| Literature DB >> 29425194 |
Champica K Bodinayake1, L Gayani Tillekeratne2,3, Ajith Nagahawatte4, Vasantha Devasiri5, Wasantha Kodikara Arachchi6, John J Strouse7, October M Sessions8, Ruvini Kurukulasooriya9, Anna Uehara8, Shiqin Howe8, Xin Mei Ong8, Sharon Tan8, Angelia Chow8, Praveen Tummalapalli8, Aruna D De Silva10, Truls Østbye3,11, Christopher W Woods2,3,12,13, Duane J Gubler3,8, Megan E Reller12,13.
Abstract
BACKGROUND: Dengue is a leading cause of fever and mimics other acute febrile illnesses (AFI). In 2009, the World Health Organization (WHO) revised criteria for clinical diagnosis of dengue. METHODOLOGY/PRINCIPALEntities:
Mesh:
Year: 2018 PMID: 29425194 PMCID: PMC5823472 DOI: 10.1371/journal.pntd.0006258
Source DB: PubMed Journal: PLoS Negl Trop Dis ISSN: 1935-2727
Comparison of clinical and laboratory features in febrile children and adults with and without acute dengue, southern Sri Lanka, 2012–2013.
| Adults | Children | |||||
|---|---|---|---|---|---|---|
| Clinical Characteristics | Acute dengue | No dengue | p-value | Acute dengue | No dengue | p-value |
| Age, yrs | 34(25–45) | 37(28–52) | 11 (7–16) | 5 (3–9) | ||
| Male | 199 (65.3%) | 227 (66.8%) | 0.68 | 51 (61.5%) | 129 (61.7%) | 0.97 |
| Days of fever | 4 (3–6) | 5 (3–7) | 0.10 | 5 (3–6) | 4 (3–6) | 0.41 |
| Headache | 251 (82.6%) | 271 (79.9%) | 0.40 | 59 (74.7%) | 101 (50.3%) | |
| Rhinitis/congestion | 30 (9.8%) | 51 (15.0%) | 0.05 | 19 (22.9%) | 104 (50.0%) | |
| Sore throat | 51 (16.7%) | 72 (21.2%) | 0.15 | 20 (24.7%) | 27 (13.4%) | |
| Cough | 108 (35.9%) | 164 (49.6%) | 31 (37.4%) | 135 (64.9%) | ||
| Joint pain | 226 (74.6%) | 198 (58.8%) | 41 (51.9%) | 48 (24.4%) | ||
| Muscle pain | 216 (71.1%) | 212 (62.9%) | 43 (54.4%) | 52 (26.5%) | ||
| Anorexia | 281 (92.4%) | 294 (86.5%) | 72 (86.8%) | 152 (72.7%) | ||
| Abdominal pain | 74 (24.3%) | 69 (20.3%) | 0.22 | 35 (43.2%) | 49 (23.7%) | |
| Vomiting | 153 (52.2%) | 133 (39.6%) | 50 (61.7%) | 104 (50.2%) | 0.08 | |
| Diarrhea | 40 (13.2%) | 48 (14.2%) | 0.72 | 3 (3.7%) | 29 (13.9%) | |
| Dysuria | 31 (10.2%) | 38 (11.2%) | 0.38 | 9 (10.8%) | 7 (3.4%) | |
| Oliguria | 39 (12.8%) | 43 (12.7%) | 0.52 | 12 (14.5%) | 13 (6.2%) | |
| Fatigue | 236 (78.2%) | 252 (74.8%) | 0.32 | 71 (88.8%) | 123 (60.6%) | |
| Temperature (C) | 100 (99–101) | 99 (98–101) | 100 (99–101) | 99 (98–100) | ||
| Heart rate / min | 80 (72–92) | 82 (76–96) | 0.06 | 100 (84–104) | 100 (88–110) | 0.06 |
| Systolic BP | 110 (110–120) | 110 (110–120) | 100 (90–110) | 100 (90–110) | 0.09 | |
| Diastolic BP | 70 (70–80) | 70 (70–80) | 0.07 | 70 (60–70) | 60 (60–70) | 0.06 |
| Conjunctival injection | 52 (17.1%) | 68 (20.1%) | 0.36 | 7 (8.4%) | 8 (3.8%) | 0.14 |
| Pharyngeal erythema/exudate | 27 (8.9%) | 21 (6.2%) | 0.23 | 5 (6.0%) | 12 (5.7%) | 1.00 |
| Lymnphadenopathy | 29 (9.8%) | 38 (11.3%) | 0.61 | 18 (21.7%) | 43 (20.7%) | 0.87 |
| Jaundice | 3 (1.0%) | 10 (3.0%) | 0.10 | 0 | 0 | — |
| Lung crackles | 10 (3.3%) | 48 (14.1%) | 3 (3.6%) | 38 (18.2%) | ||
| Right upper abdominal tenderness | 45 (14.9%) | 23 (6.8%) | 14 (17.3%) | 7 (3.4%) | ||
| Hepatomegaly | 23 (7.6%) | 24 (7.1%) | 0.88 | 6 (7.3%) | 15 (7.2%) | 1.00 |
| Rash | 56 (18.4%) | 39 (11.5%) | 20 (24.1%) | 19 (9.1%) | ||
| Flushing | 36 (11.8%) | 11 (3.2%) | 15 (18.1%) | 5 (2.4%) | ||
| WBC per μL | 3.4 (2.5–5.3) | 7.0 (4.7–10.6) | 3.4 (2.3–7.2) | 7.7 (6.1–11.2) | ||
| Leukopenia | 189 (62.4%) | 55 (16.5%) | 42 (54.6%) | 15 (9.0%) | ||
| ANC | 2.2 (1.4–3.9) | 5.0 (2.8–8.1) | 1.7 (1.1–4.8) | 4.9 (3.6–7.1) | ||
| ALC | 0.7 (0.5–1.0) | 1.2 (0.8–1.7) | 1.0 (0.6–1.8) | 2.0 (1.3–3.1) | ||
| Hemoglobin (g/dl) | 13.5 (12.4–14.6) | 13.5 (12.1–14.7) | 0.56 | 12.9 (12.2–13.5) | 12.0 (11.1–12.9) | |
| Hematocrit | 40.3 (37.0–43.7) | 40.1 (36.4–43.3) | 0.57 | 38.7 (36.6–40.6) | 36.0 (34.0–39.0) | |
| Platelets | 109 (64–157) | 174 (120–236) | 120 (72–218) | 238 (181–298) | ||
| Thrombocytopenia | 136 (44.9%) | 56 (16.8%) | 30 (39.0%) | 7 (4.2%) | ||
| Elevated transaminases | 54 (17.7%) | 34 (10.0%) | 12 (14.5%) | 1 (0.5%) | ||
| Antibiotics at enrollment | 126 (41.3%) | 216 (63.5%) | 96 (45.9%) | 28 (33.7%) | 0.06 | |
Median (range) for continuous variables or number (percentage) for categorical variables are listed in the table.
* Within 48 hrs of admission.
#Absolute neutrophil count.
^Absolute lymphocyte count.
+ within 7 days. Leukopenia: <4 x 103 cells/μL. Thrombocytopenia: <100 x 103/μL. Transaminases: AST or ALT > 120 IU, 3 times upper limit of normal).
Multivariable analysis of features associated with dengue, performed in children and adults separately, southern Sri Lanka, 2012–2013.
| Adults | Children | |||
|---|---|---|---|---|
| Characteristic | Unadjusted OR (95% CI) | Adjusted final model OR (95% CI) | Unadjusted | Adjusted final model OR (95% CI) |
| Age, yrs | 0.98 (0.97–0.99) | 0.99 (0.97–1.00) | — | — |
| Sore throat | — | — | 2.13 (1.11–4.06) | 4.43 (1.04–18.87) |
| Fatigue | — | — | 5.13 (2.43–10.85) | 10.80 (1.42–82.27) |
| Joint pain | 2.06 (1.47–2.89) | 1.72 (1.16–2.55) | — | — |
| Decreased urine output | 2.57 (1.12–5.90) | 5.32 (1.08–26.33) | ||
| Temperature | 1.25 (1.11–1.39) | 1.22 (1.07–1.39) | — | — |
| Lung crackles | 0.21 (0.10–0.42) | 0.36 (0.16–0.80) | — | — |
| Leukopenia | 8.38 (5.78–12.14) | 5.82 (3.89–8.73) | 12.16 (6.07–24.36) | 8.06 (2.64–24.56) |
| Thrombocytopenia | 4.03 (2.79–5.81) | 1.93 (1.25–2.97) | 14.41 (5.95–34.90) | 13.12 (2.86–60.17) |
| Elevated hematocrit | — | — | 1.12 (1.03–1.22) | 1.18 (1.03–1.36) |
| Elevated transaminases | 35.15 (4.49–275.19) | 43.99 (3.08–627.84) | ||
Leukopenia: <4 x 103 cells/μL, Thrombocytopenia: <100 x 103/μL. Elevated transaminases: AST or ALT > 120 IU, 3 times upper limit of normal).
Comparison of clinical and laboratory features of primary versus secondary dengue in children and adults, June 2012- May 2013, southern Sri Lanka.
| Adults | Children | |||||
|---|---|---|---|---|---|---|
| Characteristic | Primary dengue | Secondary dengue | p-value | Primary dengue | Secondary dengue | p-value |
| Age | 30.3 (24.2–43.8) | 34.1 (26.5–46.1) | 0.11 | 10.2 (5.0–15.9) | 13.3 (8.2–16.1) | 0.19 |
| Male | 45 (65.2%) | 135 (66.5%) | 0.85 | 24 (70.6%) | 22 (52.4%) | 0.11 |
| Days of fever | 4 (3–5) | 5 (3–6) | 4 (2–5) | 5 (5–6) | ||
| Rhinitis/congestion | 10 (14.5%) | 15 (7.4%) | 0.08 | 12 (35.3%) | 6 (14.3%) | |
| Sore throat | 11 (15.9%) | 33 (16.3%) | 0.95 | 11 (33.3%) | 8 (19.1%) | 0.16 |
| Cough | 33 (47.8%) | 65 (32.5%) | 14 (41.2%) | 15 (35.7%) | 0.63 | |
| Joint pain | 41 (59.4%) | 163 (81.1%) | 13 (40.6%) | 26 (61.9%) | 0.07 | |
| Muscle pain | 40 (58.5%) | 157 (77.3%) | 14 (43.8%) | 28 (66.7%) | ||
| Anorexia | 64 (92.8%) | 186 (92.1%) | 0.86 | 29 (85.3%) | 38 (90.5%) | 0.49 |
| Abdominal pain | 20 (29.0%) | 46 (22.8%) | 0.30 | 14 (41.2%) | 18 (43.9%) | 0.81 |
| Vomiting | 29 (42.7%) | 110 (56.7%) | 18 (52.9%) | 28 (70.0%) | 0.13 | |
| Diarrhea | 7 (10.1%) | 29 (14.4%) | 0.37 | 3 (8.8%) | 0 (0%) | 0.05 |
| Dysuria | 5 (7.3%) | 25 (12.3%) | 0.25 | 5 (14.7%) | 4 (9.8%) | 0.51 |
| Oliguria | 10 (14.7%) | 25 (12.3%) | 0.61 | 2 (5.9%) | 9 (22.0%) | 0.05 |
| Headache | 60 (87.0%) | 166 (82.2%) | 0.36 | 21 (65.6%) | 32 (78.1%) | 0.24 |
| Fatigue | 56 (82.4%) | 158 (78.6%) | 0.51 | 26 (78.8%) | 40 (97.6%) | |
| Temperature | 100.6 (99.2–101.0) | 99.8 (98.8–100.8) | 99.5 (98.4–100.8) | 100.3 (99.0–100.8) | 0.27 | |
| Heart rate/ min | 80 (76–88) | 80 (72–92) | 0.76 | 98 (88–110) | 96 (82–100) | 0.26 |
| Systolic BP | 110 (110–120) | 110 (100–120) | 0.15 | 100 (90–110) | 110 (100–110) | 0.04 |
| Diastolic BP | 70 (70–80) | 70 (70–80) | 0.44 | 60 (60–70) | 70 (60–70) | 0.24 |
| Conjunctival injection | 16 (23.2%) | 30 (14.8%) | 0.11 | 6 (17.7%) | 0 (0%) | |
| Pharyngeal erythema/ exudate | 4 (11.8%) | 1 (2.4%) | 0.10 | 7 (10.1%) | 17 (8.4%) | 0.65 |
| Lymphadenopathy | 9 (13.4%) | 18 (9.2%) | 0.32 | 9 (26.5%) | 7 (16.7%) | 0.30 |
| Jaundice | 0 (0%) | 2 (1.0%) | 0.41 | 0 | 0 | — |
| Lung crackles | 6 (8.7%) | 4 (2.0%) | 0.01 | 2 (5.9%) | 1 (2.4%) | 0.44 |
| Right upper abdominal tenderness | 8 (11.8%) | 32 (15.9%) | 0.41 | 8 (24.2%) | 6 (14.6%) | 0.29 |
| Hepatomegaly | 6 (8.8%) | 15 (7.5%) | 0.73 | 3 (8.8%) | 1 (2.4%) | 0.22 |
| Rash | 6 (8.7%) | 41 (20.2%) | 0.03 | 6 (17.7%) | 12 (28.6%) | 0.27 |
| Flushing | 3 (4.4%) | 28 (13.8%) | 4 (11.8%) | 10 (23.8%) | 0.18 | |
| WBC per μL | 3.5 (2.5–6.7) | 3.4 (2.4–5.1) | 0.29 | 7.3 (4.0–10.8) | 2.5 (2.2–3.8) | |
| Leukopenia | 39 (56.5%) | 127 (62.9%) | 0.35 | 7 (23.3%) | 32 (78.1%) | |
| ANC | 2.5 (1.5–4.7) | 2.1 (1.3–3.7) | 0.09 | 4.8 (1.7–6.2) | 1.3 (0.9–2.0) | |
| ALC | 0.7 (0.5–1.1) | 0.7 (0.5–0.9) | 0.67 | 1.2 (0.7–2.8) | 0.8 (0.6–1.3) | |
| Hemoglobin (g/dl) | 13.7 (12.5–14.7) | 13.6 (12.4–14.7) | 0.63 | 12.9 (11.8–13.9) | 12.9 (12.2–13.5) | 0.91 |
| Hematocrit | 41.0 (37.0–44.1) | 40.3 (37.1–43.7) | 0.65 | 38.8 (35.5–40.6) | 38.6 (37.2–41.0) | 0.71 |
| Platelets (x1000/ /μL) | 130 (88–175) | 103 (60–150) | 204 (139–261) | 84 (59–124) | ||
| Thrombocytopenia | 21 (30.4%) | 99 (49.0%) | 6 (20.0%) | 23 (56.1%) | ||
| Elevated transaminases | 2 (2.9%) | 17 (8.4%) | 0.12 | 1 (2.9%) | 3 (7.1%) | 0.42 |
| Antibiotics at enrollment | 34 (49.3%) | 79 (38.9%) | 0.13 | 11 (32.4%) | 15 (35.7%) | 0.76 |
* Within 48 hrs of Admission
#Absolute neutrophil count.
^Absolute lymphocyte count.
+ within 7 days. Leukopenia: <4 x 103 cells/μL. Thrombocytopenia: <100 x 103/μL. Elevated transaminases: AST or ALT > 120 IU, 3 times upper limit of normal). Number (proportions) listed in table except WBC and platelet count, which are listed as median (IQR).
Performance characteristics of clinical diagnosis at discharge versus the 2009 WHO classification for diagnosis of acute dengue, southern Sri Lanka, 2012–2013.
| Sensitivity (95%CI) | Specificity (95%CI) | PPV (95%CI) | NPV (95%CI) | ||
|---|---|---|---|---|---|
| All patients | Clinician diagnosis at admission | 49.0 (43.9–54.1) | 85.3 (82.0–88.1) | 70.1 (64.3–75.5) | 70.3 (66.6–73.7) |
| Clinician diagnosis at discharge | 57.7 (52.6–62.7) | 92.7 (90.2–94.7) | 84.9 (79.9–89.0) | 75.6 (72.2–78.8) | |
| WHO | 76.0 (71.5–80.2) | 64.9 (60.7–68.8) | 60.5 (56.0–64.8) | 79.3 (75.2–82.9) | |
| Children | Clinician diagnosis at admission | 50.6 (39.4–61.8) | 90.4 (85.6–94.1) | 67.7 (54.7–79.1) | 82.2 (76.6–86.9) |
| Clinician diagnosis at discharge | 50.6 (39.4–61.8) | 97.1 (93.9–98.9) | 87.5 (74.8–95.3) | 83.2 (77.9–87.7) | |
| WHO | 69.9 (58.8–79.5) | 75.1 (68.7–80.8) | 52.7 (43.0–62.3) | 86.3 (80.4–90.9) | |
| Adults | Clinician diagnosis at admission | 48.5 (42.8–54.3) | 82.1 (77.6–86.0) | 70.8 (64.1–76.9) | 64.0 (59.3–68.5) |
| Clinician diagnosis at discharge | 59.7 (53.9–65.2) | 90.0 (86.3–93.0) | 84.3 (78.7–88.9) | 71.3 (66.8–75.6) | |
| WHO | 77.7 (72.6–82.3) | 58.5 (53.1–63.8) | 62.7 (57.6–67.6) | 74.5 (68.9–79.7) | |
| Primary dengue | Clinician diagnosis at admission | 33.0 (24.1–43.0) | — | — | — |
| Clinician diagnosis at discharge | 37.9 (28.5–48.0) | — | — | — | |
| WHO | 59.2 (49.1–68.8) | — | — | — | |
| Secondary dengue | Clinician diagnosis at admission | 55.1 (48.6–61.4) | — | — | — |
| Clinician diagnosis at discharge | 66.9 (60.7–72.8) | — | — | — | |
| WHO | 83.7 (78.4–88.1) | — | — | — |
Fig 1Receiver operating characteristic (ROC) curves of the performance of the WHO classification criteria for dengue and the treating physician’s clinical diagnosis at admission and at discharge for the identification of laboratory-confirmed acute dengue in children and adults enrolled with acute febrile illness in southern Sri Lanka, 2012–2013.